NCT00114101: Phase 3 - CALGB 100104 - Lenalidomide in Patients With MM Undergoing Auto Transplant
- Active, not recruiting
- Dec 29, 2005
- 2 min read
Updated: Sep 27, 2022
CALGB 100104
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
NCT00114101: Phase 3 - CALGB 100104 - Lenalidomide in Patients With MM Undergoing Auto Transplant
This randomized phase III trial studies lenalidomide to see how well it works compared to a placebo in treating patients with multiple myeloma who are undergoing autologous stem cell transplant. Giving chemotherapy before a peripheral blood stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Biological therapies, such as lenalidomide, may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Giving lenalidomide after autologous stem cell transplant may be an effective treatment for multiple myeloma.
Sponsor
ClinicalTrials.gov Identifier: NCT00114101
Official Title: A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma
First Posted: June 14, 2005
Click here for details on ClinicalTrials.gov
PMID: 22571201
NEJM; May 2012
PMID: 28826616
Lancet Haematol; Sep 2017
* Lenalidomide (Revlimid)
- Arizona: Mayo Clinic Arizona
- California: City of Hope Duarte
- California: University of California San Diego
- Florida: Mayo Clinic Jacksonville Florida
- Illinois: University of Chicago Comprehensive Cancer Center
- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston
- Minnesota: Mayo Clinic Rochester Minnesota
- Missouri: Washington University School of Medicine Saint Louis
- New Jersey: Rutgers Cancer Institute of New Jersey New Brunswick
- New York: Roswell Park Cancer Institute Buffalo
- New York: Memorial Sloan-Kettering Cancer Center New York
- New York: New York Presbyterian / Weill Cornell Medical College New York
- New York: University of Rochester New York
- Pennsylvania: University of Pennsylvania Philadelphia
- Pennsylvania: Fox Chase Cancer Center Philadelphia
- Texas: The University of Texas MD Anderson Cancer Center Houston
Locations
United States, Arizona
United States, California
United States, Colorado
United States, Delaware
United States, District of Columbia
United States, Florida
United States, Georgia
United States, Idaho
United States, Illinois
United States, Indiana
United States, Kansas
United States, Maryland
United States, Massachusetts
United States, Minnesota
United States, Mississippi
United States, Missouri
United States, Nebraska
United States, New Jersey
United States, New Mexico
United States, New York
United States, North Carolina
United States, Ohio
United States, Oregon
United States, Pennsylvania
United States, South Carolina
United States, Tennessee
United States, Texas
United States, Utah
United States, Vermont
United States, Virginia
United States, Washington
United States, West Virginia
United States, Wisconsin
Principal Investigator: Philip L McCarthy
Alliance for Clinical Trials in Oncology